 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.190.302 |
| Chemical and physical data | |
| Formula | C24H17NO4 |
| Molar mass | 383.403 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
LY-320,135 is a drug used in scientific research which acts as a selectiveantagonist of thecannabinoid receptorCB1. It was developed byEli Lilly and Company in the 1990s.
LY-320,135 displays fairly good selectivity, with abinding affinity for CB1 around 70x stronger than for CB2,[1] but both its potency and selectivity are modest compared to newer agents, and at higher doses it also binds to a range of non-cannabinoid receptors. However LY-320,135 is still fairly widely used in research, particularly for elucidating the mechanisms by which many CB1 antagonists act asinverse agonists at higher doses.[2]
 | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |